TITLE

Malignant hyperthermia: pharmacology of triggering

AUTHOR(S)
Hopkins, P. M.
PUB. DATE
July 2011
SOURCE
BJA: The British Journal of Anaesthesia;Jul2011, Vol. 107 Issue 1, p48
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Over the past 50 yr, many drugs have been implicated as triggers of malignant hyperthermia (MH), a potentially fatal pharmacogenetic disorder of skeletal muscle calcium regulation. This review discusses the potent inhalation agents as the principal triggers and evidence that the modern agents, desflurane, sevoflurane, and isoflurane, can cause florid MH reactions in the same way as halothane but also are associated with reactions whose onset is delayed for several hours into anaesthesia. There is evidence that the triggering of MH by drugs is dose-dependent but the minimum dose that will trigger the condition is unknown. This has implications for the preparation of anaesthetic machines when used for known or suspected MH patients. While succinylcholine enhances the response of potent inhalation anaesthetics, its role as an inherent trigger of the condition is controversial. Non-depolarizing neuromuscular blocking drugs appear to protect against the development of MH and this may be by blocking excitation-coupled calcium entry—a recently described route of skeletal muscle calcium entry that may also explain the mechanism of the effect of succinylcholine in MH. Another mechanism for extracellular calcium influx, store-operated calcium entry, is activated in MH muscle and may explain how a triggered reaction is sustained. Finally, reports of drugs that have been implicated as additional triggers of MH over the past 10 yr are discussed.
ACCESSION #
61782420

 

Related Articles

  • Prevention and treatment of malignant hyperthermia in certified training hospitals in Japan: a questionnaire. Suyama, Hidemichi; Kawamoto, Masashi; Yuge, Osafumi // Journal of Anesthesia;2002, Vol. 16 Issue 3, p207 

    .Purpose. To assess the preparedness of hospitals in Japan for cases of malignant hyperthermia (MH).Method. A survey was sent to 884 training hospitals certified by the Japan Society of Anesthesiologists (JSA) in June and July 2000. Useful answers were received from 431 (48.8%)...

  • Synthesis and Structure-Activity Relationships of Neuromuscular Blocking Agents. Tuba, Zoltan; Maho, Sandor; Vizi, E. Sylvester // Current Medicinal Chemistry;Aug2002, Vol. 9 Issue 16, p1507 

    The first use of neuromuscular blocking agents (muscle relaxants) in clinical practice (1942) revolutionised the practice of anaesthesia and started the modern era of surgery. Since 1942 introduction of tubocurarine (18) neuromuscular blocking agents have been used routinely to provide skeletal...

  • Renal Transplantation from an Unrelated Living Donor to a Malignant Hyperthermia-Susceptible Patient: A Case Report. Kern, Marli // AANA Journal;Oct2011, Vol. 79 Issue 5, p397 

    A 56-year-old patient with renal insufficiency secondary to Alport syndrome presented for kidney transplantation from an unrelated living donor. The recipient had a medical history that included 2 episodes of malignant hyperthermia: in 1989 and 1991. On both occasions she was treated with...

  • Everybody's talking about Dysport The Timing's Just Right!  // Plastic Surgery Practice;Dec2009, Vol. 19 Issue 13, p10 

    The article presents information on the drug Dysport which is an acetylcholine release inhibitor and a neuromuscular blocking agent. It focuses on the dosage and administration of the drug. The article reports the adverse reactions that were noted in the clinical studies including headache,...

  • Anesthesia Considerations in a Patient With McArdle Disease: A Case Report. Choleva, Abbie J. // AANA Journal;Jun2011, Vol. 79 Issue 3, p243 

    A patient with McArdle disease underwent bowel surgery with general anesthesia and was successfully managed. McArdle disease is a rare skeletal muscle disorder affecting approximately 1 in 100,000 people. McArdle disease, also known as type V glycogen storage disease, is an autosomal recessive...

  • Kardiorelax 2011 -- petidenn� dotazn�kov� studie svalov� relaxace behem kardiochirurgick�ch v�konu v Cesk� republice. Roman, H�jek; Petr, Ad�mek; Leo, Derych; Michal, Hor�cek; Pavel, Jehlicka; Vladim�r, Kamen�k; Mari�n, Leitgeb; Jir�, Mokrej�; Hynek, R�ha; Jindrich, Samek; Tom�, Schichel; Zdenek, Turek; Tom�, Vanek // Anaesthesiology & Intensive Medicine / Anesteziologie a Intenziv;Feb2012, Vol. 23 Issue 1, p14 

    Objective: To obtain data about the use of neuromuscular blocking agents (NMBAs) during general anaesthesia in adult patients undergoing cardiac surgery in the Czech Republic. Design: A five-day, prevalence, questionnaire study. Setting: All cardiac anesthesia departments that registered before...

  • PHARMACOLOGY CLINICAL.  // BJA: The British Journal of Anaesthesia;Mar2012 Supplement 2, Vol. 108, pii368 

    No abstract available.

  • Pharmacology of neuromuscular blocking drugs. Appiah-Ankam, Jonas; Hunter, Jennifer M. // Continuing Education in Anaesthesia, Critical Care & Pain;Feb2004, Vol. 4 Issue 1, p2 

    Neuromuscular blocking drugs (NMBDs) have become an established part of anaesthetic practice since Griffith and Johnson in Montreal first described the use of curare to facilitate muscle relaxation in a healthy man undergoing an appendicectomy in 1942.

  • Determining the potency of neuromuscular blockers: are traditional methods flawed? Kopman, A. F.; Lien, C. A.; Naguib, M. // BJA: The British Journal of Anaesthesia;Jun2010, Vol. 104 Issue 6, p705 

    Background: Traditionally, the clinical potency of neuromuscular blocking drugs has been measured using linear regression analysis (LRA) after log dose and probit or logit data transformation. However, probit and logit analyses are meant to handle only quantal responses with binomial error...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics